Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2018

11.12.2017 | Epidemiology

Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors

verfasst von: Sarah J. O. Nomura, Yi-Ting Hwang, Scarlett Lin Gomez, Teresa T. Fung, Shu-Lan Yeh, Chiranjeev Dash, Laura Allen, Serena Philips, Leena Hilakivi-Clarke, Yun-Ling Zheng, Judy Huei-yu Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors.

Methods

This cross-sectional study included 192 CA and 173 NHW female breast cancer survivors (stages 0–III, diagnosed between 2006 and 2012) recruited from two California cancer registries, who had completed primary treatment. Patient-reported data on treatment-related symptoms and potential covariates were collected via telephone interviews. Dietary data were ascertained by mailed questionnaires. The outcomes evaluated were menopausal symptoms (hot flashes, night sweats, vaginal dryness, vaginal discharge), joint problems, fatigue, hair thinning/loss, and memory problems. Associations between soy and cruciferous vegetables and symptoms were assessed using logistic regression. Analyses were further stratified by race/ethnicity and endocrine therapy usage (non-user, tamoxifen, aromatase inhibitors).

Results

Soy food and cruciferous vegetable intake ranged from no intake to 431 and 865 g/day, respectively, and was higher in CA survivors. Higher soy food intake was associated with lower odds of menopausal symptoms (≥ 24.0 vs. 0 g/day, OR 0.51, 95% CI 0.25, 1.03), and fatigue (≥ 24.0 vs. 0 g/day, OR 0.43, 95% CI 0.22, 0.84). However, when stratified by race/ethnicity, associations were statistically significant in NHW survivors only. Compared with low intake, higher cruciferous vegetable intake was associated with lower odds of experiencing menopausal symptoms (≥ 70.8 vs. < 33.0 g/day, OR 0.50, 95% CI 0.25, 0.97) in the overall population.

Conclusions

In this population of breast cancer survivors, higher soy and cruciferous vegetable intake was associated with less treatment-related menopausal symptoms and fatigue.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
8.
Zurück zum Zitat Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society/American Society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol 34(6):611–635. https://doi.org/10.1200/JCO.2015.64.3809 CrossRefPubMed Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society/American Society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol 34(6):611–635. https://​doi.​org/​10.​1200/​JCO.​2015.​64.​3809 CrossRefPubMed
11.
Zurück zum Zitat Messina MJ, Loprinzi CL (2001) Soy for breast cancer survivors: a critical review of the literature. J Nutr 131(11):3095S–3108SCrossRefPubMed Messina MJ, Loprinzi CL (2001) Soy for breast cancer survivors: a critical review of the literature. J Nutr 131(11):3095S–3108SCrossRefPubMed
12.
Zurück zum Zitat Setchell KDR, Cassidy A (1999) Dietary isoflavones: biological effects and relevance to human health. J Nutr 129(3):758CrossRef Setchell KDR, Cassidy A (1999) Dietary isoflavones: biological effects and relevance to human health. J Nutr 129(3):758CrossRef
14.
Zurück zum Zitat Kronenberg F, Fugh-Berman A (2002) Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 137(10):805–813CrossRefPubMed Kronenberg F, Fugh-Berman A (2002) Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 137(10):805–813CrossRefPubMed
19.
Zurück zum Zitat Nikander E, Kilkkinen A, Metsa-Heikkila M, Adlercreutz H, Pietinen P, Tiitinen A, Ylikorkala O (2003) A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 101(6):1213–1220PubMed Nikander E, Kilkkinen A, Metsa-Heikkila M, Adlercreutz H, Pietinen P, Tiitinen A, Ylikorkala O (2003) A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 101(6):1213–1220PubMed
21.
Zurück zum Zitat Keck AS, Finley JW (2004) Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr Cancer Ther 3:5–12CrossRefPubMed Keck AS, Finley JW (2004) Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr Cancer Ther 3:5–12CrossRefPubMed
25.
Zurück zum Zitat Steinkellner H, Rabot S, Freywald C, Nobis E, Scharf G, Chabicovsky M, Knasmuller S, Kassie F (2001) Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 480–481:285–297CrossRefPubMed Steinkellner H, Rabot S, Freywald C, Nobis E, Scharf G, Chabicovsky M, Knasmuller S, Kassie F (2001) Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 480–481:285–297CrossRefPubMed
28.
Zurück zum Zitat Portenoy RK, thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed Portenoy RK, thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefPubMed
33.
Zurück zum Zitat Hakim IA, Hartz V, Harris RB, Balentine D, Weisgerber UM, Graver E, Whitacre R, Alberts D (2001) Reproducibility and relative validity of a questionnaire to assess intake of black tea polyphenols in epidemiological studies. Cancer Epidemiol Biomark Prev 10(6):667–678 Hakim IA, Hartz V, Harris RB, Balentine D, Weisgerber UM, Graver E, Whitacre R, Alberts D (2001) Reproducibility and relative validity of a questionnaire to assess intake of black tea polyphenols in epidemiological studies. Cancer Epidemiol Biomark Prev 10(6):667–678
35.
Zurück zum Zitat Martinez ME, Marshall JR, Graver E, Whitacre RC, Woolf K, Ritenbaugh C, Alberts DS (1999) Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomark Prev 8(10):941–946 Martinez ME, Marshall JR, Graver E, Whitacre RC, Woolf K, Ritenbaugh C, Alberts DS (1999) Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomark Prev 8(10):941–946
36.
Zurück zum Zitat Thomson CA, Giuliano A, Rock CL, Ritenbaugh CK, Flatt SW, Faerber S, Newman V, Caan B, Graver E, Hartz V, Whitacre R, Parker F, Pierce JP, Marshall JR (2003) Measuring dietary change in a diet intervention trial: comparing food frequency questionnaire and dietary recalls. Am J Epidemiol 157(8):754–762CrossRefPubMed Thomson CA, Giuliano A, Rock CL, Ritenbaugh CK, Flatt SW, Faerber S, Newman V, Caan B, Graver E, Hartz V, Whitacre R, Parker F, Pierce JP, Marshall JR (2003) Measuring dietary change in a diet intervention trial: comparing food frequency questionnaire and dietary recalls. Am J Epidemiol 157(8):754–762CrossRefPubMed
39.
Zurück zum Zitat Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exercise 35:1381–1395CrossRef Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exercise 35:1381–1395CrossRef
42.
50.
51.
Zurück zum Zitat Zhang YF, Kang HB, Zhang RM (2012) Positive effects of soy isoflavone food on survival of breast cancer patients in China. Asian Pac J Cancer Prev 13:479–482CrossRefPubMed Zhang YF, Kang HB, Zhang RM (2012) Positive effects of soy isoflavone food on survival of breast cancer patients in China. Asian Pac J Cancer Prev 13:479–482CrossRefPubMed
56.
Zurück zum Zitat Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ (2000) evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 18(5):1068CrossRefPubMed Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ (2000) evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 18(5):1068CrossRefPubMed
57.
Zurück zum Zitat Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, Hase T (1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 25(5B):791–797CrossRefPubMed Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, Hase T (1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 25(5B):791–797CrossRefPubMed
61.
Zurück zum Zitat Yuan-Di X, Xiao-Ying L, Juan D, Huan-Ling Y, Wei-Wei M, Lin-Hong Y, Jian W, Rong X (2013) Soy isoflavone alleviates Aβ1-42-induced impairment of learning and memory ability through the regulation of RAGE/LRP-1 in neuronal and vascular tissue. Curr Neurovascular Res 10(2):144–156. https://doi.org/10.2174/1567202611310020007 CrossRef Yuan-Di X, Xiao-Ying L, Juan D, Huan-Ling Y, Wei-Wei M, Lin-Hong Y, Jian W, Rong X (2013) Soy isoflavone alleviates Aβ1-42-induced impairment of learning and memory ability through the regulation of RAGE/LRP-1 in neuronal and vascular tissue. Curr Neurovascular Res 10(2):144–156. https://​doi.​org/​10.​2174/​1567202611310020​007 CrossRef
62.
Zurück zum Zitat Cheng PF, Chen JJ, Zhou XY, Ren YF, Huang W, Zhou JJ, Xie P (2015) Do soy isoflavones improve cognitive function in postmenopausal women? a meta-analysis. Menopause 22:198–206CrossRefPubMed Cheng PF, Chen JJ, Zhou XY, Ren YF, Huang W, Zhou JJ, Xie P (2015) Do soy isoflavones improve cognitive function in postmenopausal women? a meta-analysis. Menopause 22:198–206CrossRefPubMed
Metadaten
Titel
Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
verfasst von
Sarah J. O. Nomura
Yi-Ting Hwang
Scarlett Lin Gomez
Teresa T. Fung
Shu-Lan Yeh
Chiranjeev Dash
Laura Allen
Serena Philips
Leena Hilakivi-Clarke
Yun-Ling Zheng
Judy Huei-yu Wang
Publikationsdatum
11.12.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4578-9

Weitere Artikel der Ausgabe 2/2018

Breast Cancer Research and Treatment 2/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.